Pacira | PCRX - Cash And Equivalent

Stock Price
20.64
Daily Change
0.28 1.38%
Monthly
-20.62%
Yearly
-20.92%
Q1 Forecast
19.91

Pacira reported $147.59M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Astellas Pharma JPY 188.37B 8.51B Mar/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Xeris Pharmaceuticals USD 91.6M 32.32M Sep/2025
Zoetis USD 2.08B 649M Sep/2025